However, the drug belonging to a class of treatments called SGLT2 inhibitors did not show a statistically significant benefit for the prevention of cardiac or stroke attacks, even in patients with diagnosed cardiovascular disease.
Diabetics have an increased risk of heart problems, which means that cardiovascular drugs can benefit from important attention from doctors and patients.
Stephen Wiviott of Brigham and Boston Women's Hospital, senior researchers in this cynical study, said that these findings are important for making a clear picture of SGLT2 drugs that have so far been targeted to patients with diagnosed carcasses.
AstraZeneca hopes that the new data will help expand the use of Farxiga to a larger number of patients.
The key findings of the clinical study declared, conducted at a cohort of 17,000 patients, were not announced until September, but details were revealed on Saturday at the American Heart Association Annual Meeting and published simultaneously in the New England Journal of Medicine.
These results have shown that Farxiga reduces the risk of hospital care by 27% due to heart problems, as well as the risk of kidney disease.
While two minor studies of competing SGLT2 drugs focused on patients with diagnosed heart disease, Wiviott said that the overall picture of the declared study showed that widespread cardiac arrest is the main advantage.
"When analyzing the three studies it is clear that the primary benefit of this class of cardiovascular disease is to reduce heart failure," said Wiviott.
For decades, diabetics have mainly focused on reducing blood glucose levels at certain levels. However, the predisposition of diabetics to other problems, such as heart failure, where five-year survival is only 50%, indicates that a more holistic approach is needed, says Wiviott.
"The message at the moment is that how we reduce glucose levels can be as important as the percentage we do. We should choose drugs that improve patients' lifespan, not just drugs that have an effect on reducing blood glucose," said the doctor.
Farxiga competes with competing SGLT2 drugs, including Jardiance, produced by Eli Lilly and Boehringer Ingelheim and Invokana Johnson & Johnson, who have already shown increased lifespan for patients diagnosed with heart problems, known as secondary prevention.
Since the AstraZeneca process also evaluated patients without diagnosed cardiovascular disease, this study opens a broader market that includes primary prevention.
The Declare study did not identify any increased risk of amputations, fractures, bladder or coronary artery disease in patients treated with Farxiga, problems that were sometimes observed in patients treated with SGLT, but there has been an increase in genital infections.